Koren-Michowitz, Maya ORCID: 0000-0002-7223-328X, le Coutre, Philipp, Duyster, Justus, Scheid, Christof, Panayiotidis, Panayiotis, Prejzner, Witold, Rowe, Jacob M., Schwarz, Michaela, Goldschmidt, Neta and Nagler, Arnon (2010). Activity and Tolerability of Nilotinib A Retrospective Multicenter Analysis of Chronic Myeloid Leukemia Patients Who Are Imatinib Resistant or Intolerant. Cancer, 116 (19). S. 4564 - 4573. HOBOKEN: WILEY. ISSN 1097-0142

Full text not available from this repository.

Abstract

BACKGROUND: Nilotinib is active in imatinib-resistant and -intolerant chronic myeloid leukemia patients and was recently approved for these indications. METHODS: Data on the efficacy and safety of nilotinib treatment were collected from 2 phase 2 expanded access clinical trials with similar designs (CAMN107AIL01 and ENACT). RESULTS: Of 88 study patients (58 chronic, 11 accelerated, 19 blast crisis), the best responses to nilotinib were complete hematologic response (CHR) in 27%, partial cytogenetic response in 12%, complete cytogenetic response in 14%, and major molecular response in 19%. Patients achieving at least a CHR during imatinib therapy were more likely to respond to nilotinib, and failure to achieve at least a CHR on imatinib therapy was predictive of progression or lack of response to nilotinib (P = .0021). Responses were not statistically different in subgroup analysis, including that of imatinib intolerance compared with imatinib resistance, presence of ABL kinase domain mutations compared with absence of mutations, and previous treatment with another second-generation tyrosine kinase inhibitor compared no prior treatment. The overall survival and progression-free survival rates at 1 year were 83% and 48% for the entire cohort, 93% and 66% in chronic phase, and 64% and 19% in advanced phase. Adverse hematological events included thrombocytopenia (all events, 27%; grade 3-4, 13%) and leukopenia (all events, 18%; grade 3-4, 10%). The majority of the nonhematological events were mild, the most common being rash, infection, bone pain, headache, nausea, and vomiting. CONCLUSIONS: Nilotinib treatment is an efficient and safe therapy for imatinib-resistant or -intolerant patients. Prior response to imatinib therapy is a predictor for the response to nilotinib. Cancer 2010;116:4564-72. (C) 2010 American Cancer Society.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Koren-Michowitz, MayaUNSPECIFIEDorcid.org/0000-0002-7223-328XUNSPECIFIED
le Coutre, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duyster, JustusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Panayiotidis, PanayiotisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Prejzner, WitoldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rowe, Jacob M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schwarz, MichaelaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goldschmidt, NetaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nagler, ArnonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-495181
DOI: 10.1002/cncr.25351
Journal or Publication Title: Cancer
Volume: 116
Number: 19
Page Range: S. 4564 - 4573
Date: 2010
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1097-0142
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITOR; IN-VITRO ACTIVITY; BCR-ABL; CYTOGENETIC RESPONSES; POINT MUTATIONS; FORMERLY AMN107Multiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/49518

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item